- Home
- FBRX vs ADVB Comparison
FBRX vs ADVB Comparison
Compare FBRX & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- ADVB
- Stock Information
- Founded
- FBRX N/A
- ADVB 2014
- Country
- FBRX United States
- ADVB United States
- Employees
- FBRX N/A
- ADVB N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- ADVB Medical Specialities
- Sector
- FBRX Health Care
- ADVB Health Care
- Exchange
- FBRX Nasdaq
- ADVB Nasdaq
- Market Cap
- FBRX 35.3M
- ADVB 36.1M
- IPO Year
- FBRX N/A
- ADVB 2025
- Fundamental
- Price
- FBRX $6.80
- ADVB $1.02
- Analyst Decision
- FBRX Strong Buy
- ADVB
- Analyst Count
- FBRX 3
- ADVB 0
- Target Price
- FBRX $80.50
- ADVB N/A
- AVG Volume (30 Days)
- FBRX 26.6K
- ADVB 184.1K
- Earning Date
- FBRX 05-20-2025
- ADVB 01-01-0001
- Dividend Yield
- FBRX N/A
- ADVB N/A
- EPS Growth
- FBRX N/A
- ADVB N/A
- EPS
- FBRX N/A
- ADVB N/A
- Revenue
- FBRX N/A
- ADVB N/A
- Revenue This Year
- FBRX N/A
- ADVB N/A
- Revenue Next Year
- FBRX N/A
- ADVB N/A
- P/E Ratio
- FBRX N/A
- ADVB N/A
- Revenue Growth
- FBRX N/A
- ADVB N/A
- 52 Week Low
- FBRX $4.11
- ADVB $1.01
- 52 Week High
- FBRX $28.68
- ADVB $4.10
- Technical
- Relative Strength Index (RSI)
- FBRX 50.51
- ADVB N/A
- Support Level
- FBRX $6.20
- ADVB N/A
- Resistance Level
- FBRX $6.91
- ADVB N/A
- Average True Range (ATR)
- FBRX 0.61
- ADVB 0.00
- MACD
- FBRX 0.01
- ADVB 0.00
- Stochastic Oscillator
- FBRX 52.63
- ADVB 0.00
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).
About ADVB Advanced Biomed Inc. Common Stock
Advanced Biomed Inc operates through its subsidiaries that are responsible for the main operation and the design and development of the company's primary technologies and products. It has been focusing on the integration of multiple interdisciplinary technologies and established its microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, the company has developed various advanced and original research through the joint application of semiconductor technology and biotechnology. devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.